Evidence map›Paper›PMID 32882024›Full record

ArticleJournal of the National Cancer Institute2021

Genome-Wide Association Study of Susceptibility Loci for TCF3-PBX1 Acute Lymphoblastic Leukemia in Children.

Shawn H R Lee, Maoxiang Qian, Wentao Yang, Jonathan D Diedrich, Elizabeth Raetz, Wenjian Yang, Qian Dong, Meenakshi Devidas, Deqing Pei, Allen Yeoh and 9 more

Abstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Shawn H R LeeDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Maoxiang QianInstitute of Pediatrics and Department of Hematology and Oncology, Children's Hospital of Fudan University, Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Wentao YangDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Jonathan D DiedrichDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Elizabeth RaetzDivision of Pediatric Hematology and Oncology, New York University Langone Health, New York, NY, USA.
Wenjian YangDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-7305-5649
Qian DongDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Meenakshi DevidasDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.
Deqing PeiDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA.
Allen YeohKhoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore.
Cheng ChengDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA.
Ching-Hon PuiDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
William E EvansDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Charles G MullighanDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Stephen P HungerDepartment of Pediatrics and Center for Childhood Cancer Research, Children's Hospital of Philadelphia and the Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA, USA.
Daniel SavicDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Mary V RellingDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Mignon L LohDepartment of Pediatrics, Benioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Jun J YangDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-0770-9659

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Children's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DEVIDAS, MEENAKSHI · 2003 to 2013
$67.5M
CPML - Project 3: Genome-wide Studies of Adverse EffectsP50GM115279 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2015 to 2019
$15.1M
Support for Human Specimen Banking in NCI-Supported Cancer Clinical TrialsU24CA114766 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI RAMIREZ MILAN, NILSA DEL CARMEN · 2005 to 2014
$14.5M
Translating genomic discoveries to improved outcomes for high risk acute leukemiaR35CA197695 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Charles G Mullighan · 2017 to 2026
$11.4M
PAARK4Kids-Pharmacogenomics of Anticancer Agents Research in ChildrenU01GM092666 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2010 to 2014
$8.9M
NEXT GENERATION SEQUENCING ADD-ON-PHARMACOGENOMICS RESEARCH NETWROK (PGRN)U01GM097119 · NIGMS · WASHINGTON UNIVERSITY · PI MARDIS, ELAINE R · 2010 to 2014
$2.6M
Characterizing noncoding GWAS variants in acute lymphoblastic leukemia treatment outcomeR01CA234490 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI SAVIC, DANIEL · 2019 to 2023
$2.4M
NCI NIH HHS P30 CA021765NCI NIH HHS R01 CA234490NCI NIH HHS R35 CA197695NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U24 CA114766NIGMS NIH HHS P50 GM115279NIGMS NIH HHS U01 GM092666NIGMS NIH HHS U01 GM097119
6 · The paper itself

Abstract

Acute lymphoblastic leukemia (ALL) is the most common cancer in children. TCF3-PBX1 fusion defines a common molecular subtype of ALL with unique clinical features, but the molecular basis of its inherited susceptibility is unknown. In a genome-wide association study of 1494 ALL cases and 2057 non-ALL controls, we identified a germline risk locus located in an intergenic region between BCL11A and PAPOLG: rs2665658, P = 1.88 × 10-8 for TCF3-PBX1 ALL vs non-ALL, and P = 1.70 × 10-8 for TCF3-PBX1 ALL vs other-ALL. The lead variant was validated in a replication cohort, and conditional analyses pointed to a single causal variant with subtype-specific effect. The risk variant is located in a regulatory DNA element uniquely activated in ALL cells with the TCF3-PBX1 fusion and may distally modulate the transcription of the adjacent gene REL. Our results expand the understanding of subtype-specific ALL susceptibility and highlight plausible interplay between germline variants and somatic genomic abnormalities in ALL pathogenesis.

Indexed as

Genome-Wide Association StudyPrecursor Cell Lymphoblastic Leukemia-LymphomaAcute DiseaseBasic Helix-Loop-Helix ProteinsGenetic Predisposition to DiseaseHumansOncogene Proteins, FusionPre-B-Cell Leukemia Transcription Factor 1Basic Helix-Loop-Helix ProteinsOncogene Proteins, FusionPBX1 protein, humanPre-B-Cell Leukemia Transcription Factor 1TCF3-PBX1 fusion protein, humanTCF3 protein, human

Identifiers

PMID32882024
PMCPMC8487647

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.